ENLV

Enlivex Therapeutics Ltd. [ENLV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ENLV Stock Summary

ENLV has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

ENLV

Top 10 Correlated Stocks

ENLV

In the News

08:00 29 Sep 2023 ENLV

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the 2023 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 11:30 AM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff281/enlv/1860430, and will be archived for 90 days.

08:13 29 Sep 2023 ENLV

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022.

02:08 29 Sep 2023 ENLV

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Enlivex Therapeutics: The early results for Allocetra for sepsis (in humans) and solid tumors (in mice) look incredible. The share offering from 2021 shows a willingness to protect existing shareholders.

08:00 29 Sep 2023 ENLV

Enlivex to Present at the 2022 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that company management will present a corporate update at the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 1:00 PM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff240/enlv/1853925 , and will be archived for 90 days.

10:48 29 Sep 2023 ENLV

Enlivex Therapeutics Stock (ENLV): Why The Price Increased Today

The stock price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) increased by over 4% during intraday trading today. This is why it happened.

08:00 29 Sep 2023 ENLV

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine

Publication follows the Israeli Ministry of Health's appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines

08:48 29 Sep 2023 ENLV

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021

Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the Reuters Events' Cell & Gene Therapy USA 2021 event, which is taking place virtually on September 28 and 29, 2021.

07:45 29 Sep 2023 ENLV

Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?

Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.

11:27 29 Sep 2023 ENLV

Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy

Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.

06:00 29 Sep 2023 ENLV

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS

ENLV Financial details

Company Rating

Buy

Market Cap

27.15M

Income

-26.77M

Revenue

Book val./share

2.39

Cash/share

1.56

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

15 Dec 2023

P/E

-1.04

Forward P/E

PEG

-0.06

P/S

P/B

0.63

P/C

P/FCF

-0.99

Quick Ratio

6.17

Current Ratio

6.17

Debt / Equity

0.1

LT Debt / Equity

0.08

EPS (TTM)

-1.45

EPS next Y

EPS next Q

EPS this Y

327.78%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-9.76%

SMA20

SMA50

SMA100

-33.33%

Inst Own

1.64%

Inst Trans

0.88%

ROA

-50%

ROE

-50%

ROC

-0.56%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

18.6M

Shs Float

14.5M

Target Price

52W Range

1.4503-4.92

52W High

-61%

52W Low

+56%

RSI

Rel Volume

0.18

Avg Volume

23.82K

Volume

4.4K

Perf Week

-0.64%

Perf Month

-37.85%

Perf Quarter

-44.29%

Perf Half Y

-54.78%

Beta

0.594689

Volatility

0.06%, 0.37%

Prev Close

Price

1.56

Change

-2.34%

ENLV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0.17	0	0
Net income per share	-1.21	-1.17	-1.05	-0.54	-2.31
Operating cash flow per share	-0.9	-0.81	-0.84	-0.98	-1.3
Free cash flow per share	-1.03	-0.84	-0.91	-1.07	-1.74
Cash per share	2.79	1.39	2.71	4.71	2.62
Book value per share	2.77	1.3	2.69	4.76	3.09
Tangible book value per share	2.77	1.26	2.69	4.76	3.09
Share holders equity per share	2.77	1.3	2.69	4.76	3.09
Interest debt per share	0	0.01	0.02	0.03	0.55
Market cap	21.72M	72.57M	111.02M	111.62M	72.48M
Enterprise value	11.99M	68.74M	105.55M	101.04M	29.5M
P/E ratio	-5.12	-7.15	-8.01	-11.57	-1.71
Price to sales ratio	0	0	48.76	0	0
POCF ratio	-6.87	-10.31	-10.09	-6.36	-3.03
PFCF ratio	-6	-10.03	-9.23	-5.82	-2.26
P/B Ratio	2.24	6.43	3.13	1.31	1.28
PTB ratio	2.24	6.43	3.13	1.31	1.28
EV to sales	0	0	46.35	0	0
Enterprise value over EBITDA	-1.97	-9.27	-14.58	-4.25	-1.56
EV to operating cash flow	-3.79	-9.76	-9.59	-5.76	-1.23
EV to free cash flow	-3.31	-9.5	-8.78	-5.27	-0.92
Earnings yield	-0.2	-0.14	-0.12	-0.09	-0.59
Free cash flow yield	-0.17	-0.1	-0.11	-0.17	-0.44
Debt to equity	0	0.01	0.01	0.01	0.09
Debt to assets	0	0.01	0.01	0.01	0.07
Net debt to EBITDA	1.6	0.52	0.76	0.45	2.27
Current ratio	9.09	2.75	8.72	18.32	7.92
Interest coverage	0	0	0	0	-4.9
Income quality	0.75	0.75	0.93	1.21	0.77
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	1.58	0	0
Research and developement to revenue	0	0	2.67	0	0
Intangibles to total assets	0	0.02	0	0	0
Capex to operating cash flow	0.15	0.03	0.09	0.09	0.34
Capex to revenue	0	0	-0.45	0	0
Capex to depreciation	-3.81	-0.94	-3.56	-2.98	-10.45
Stock based compensation to revenue	0	0	0.29	0	0
Graham number	8.67	5.87	7.99	7.61	12.66
ROIC	-0.68	-0.81	-0.32	-0.15	-0.56
Return on tangible assets	-0.38	-0.59	-0.34	-0.1	-0.63
Graham Net	2.45	0.87	1.22	3.9	2.09
Working capital	9.15M	10.44M	33.75M	81.72M	45.72M
Tangible asset value	9.71M	10.87M	35.49M	85.04M	56.84M
Net current asset value	8.95M	10.14M	33.25M	76.34M	41.53M
Invested capital	0	0.01	0.01	0.01	0.09
Average receivables	120.5K	1.31M	1.78M	1.68M	1.42M
Average payables	96K	244.5K	389.5K	670.5K	1.41M
Average inventory	0	0	-15.6M	-21.7M	-5.51M
Days sales outstanding	0	0	186.59	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	1.96	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.44	-0.9	-0.39	-0.11	-0.75
Capex per share	-0.13	-0.02	-0.08	-0.09	-0.44

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	0	0	0	0	0
Net income per share	-0.76	-0.31	-0.36	-0.41	-0.37
Operating cash flow per share	-0.5	-0.36	-0.26	-0.31	-0.38
Free cash flow per share	-0.69	-0.42	-0.4	-0.32	-0.38
Cash per share	3.4	2.1	2.62	1.94	1.56
Book value per share	3.73	3.44	3.09	2.73	2.39
Tangible book value per share	3.73	3.44	3.09	2.73	2.39
Share holders equity per share	3.73	3.44	3.09	2.73	2.39
Interest debt per share	0.25	0.29	0.23	0.28	0.24
Market cap	83.06M	78.17M	72.48M	67.4M	48.7M
Enterprise value	63.53M	44.87M	29.5M	58.94M	49.61M
P/E ratio	-1.49	-3.38	-2.77	-2.2	-1.79
Price to sales ratio	0	0	0	0	0
POCF ratio	-8.96	-11.86	-15.04	-11.65	-6.93
PFCF ratio	-6.55	-10.04	-9.8	-11.34	-6.9
P/B Ratio	1.21	1.24	1.28	1.33	1.1
PTB ratio	1.21	1.24	1.28	1.33	1.1
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-11.16	-8.18	-3.87	-8.97	-7.71
EV to operating cash flow	-6.85	-6.81	-6.12	-10.19	-7.06
EV to free cash flow	-5.01	-5.77	-3.99	-9.91	-7.03
Earnings yield	-0.17	-0.07	-0.09	-0.11	-0.14
Free cash flow yield	-0.15	-0.1	-0.1	-0.09	-0.14
Debt to equity	0.01	0.08	0.09	0.09	0.1
Debt to assets	0.01	0.07	0.07	0.08	0.08
Net debt to EBITDA	3.43	6.07	5.64	1.29	-0.14
Current ratio	15.44	13.08	7.92	6.89	6.17
Interest coverage	-1.45	-101.38	11.96	-15.59	0
Income quality	0.94	1.15	0.67	0.8	1.03
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.37	0.18	0.54	0.03	0.01
Capex to revenue	0	0	0	0	0
Capex to depreciation	-19.31	-6.2	-11.68	-0.78	-0.18
Stock based compensation to revenue	0	0	0	0	0
Graham number	7.98	4.94	4.97	5.04	4.45
ROIC	-0.12	-0.08	-0.11	-0.12	-0.13
Return on tangible assets	-0.18	-0.08	-0.1	-0.13	-0.13
Graham Net	3.02	2.18	2.09	1.5	1.17
Working capital	60.84M	54.7M	45.72M	32.13M	25.79M
Tangible asset value	68.49M	63.27M	56.84M	50.57M	44.34M
Net current asset value	56.2M	50.09M	41.53M	28.13M	22.09M
Invested capital	0.01	0.08	0.09	0.09	0.1
Average receivables	1.82M	1.96M	1.06M	1.13M	1.74M
Average payables	1.01M	861.5K	1.5M	1.72M	1.52M
Average inventory	0	9.55M	10.14M	588.5K	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.2	-0.09	-0.11	-0.15	-0.15
Capex per share	-0.18	-0.06	-0.14	-0.01	0

ENLV Frequently Asked Questions

What is Enlivex Therapeutics Ltd. stock symbol ?

Enlivex Therapeutics Ltd. is a IL stock and trading under the symbol ENLV

Is Enlivex Therapeutics Ltd. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $15. The lowest prediction is $15 and the highest is $15

What is ENLV stock prediction ?

What is Enlivex Therapeutics Ltd. stock quote today ?

Enlivex Therapeutics Ltd. stock price is $1.56 today.

Is Enlivex Therapeutics Ltd. stock public?

Yes, Enlivex Therapeutics Ltd. is a publicly traded company.

Something similar

Top by Market Cap

DHR-PB

MSF.BR

Company Profile

Volume Average 23.82K
Market Capitalization 27.15M
Employee 71
CEO Mr. Shai Novik M.B.A.
Headquarters Ness Ziona,IL
IPO Date 2014-07-31
Website https://www.enlivex.com

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.